Parkinsonism and other movement disorders in outpatients in chronic use of cinnarizine and flunarizine.
The purpose of this study is to determine the prevalence and the patterns of movement disorders (MD) in outpatients submitted to the chronic use of cinnarizine (cz) or flunarizine (fz), and to establish the main risk factors for MD development. Over a period of 3 months, data were collected from outpatients who were chronic users of cz or fz in a municipal health institute. A total of 26 outpatients were included and all of them were submitted to a protocol that included DSM-4 diagnosis criteria for drug-induced movement disorders, parkinsonism (PK) and depression. Parkinsonism was diagnosed in 34% of the patients, PK plus akathisia, PK plus akathisia and bucco-linguo-masticatory syndrome (BLMS), isolated BLMS and dystonia were found in 4% patients each. Patients with BLMS had the highest median age and the longest average period in which they used the drugs. The affected group, when compared to the non-affected one, presented with higher rates of depression. This study demonstrates the existence of a direct relationship between the time of use of cz and fz, the age and the prevalence of PK and other MD. It also suggests that these drugs increase the incidence of depression.
Fabiani
Giorgio
G
NEUROVITA, Hospital VITA de Curitiba, PR, Brazil. giorgiofabiani@aol.com
Pastro
Paulo C
PC
Froehner
Carolina
C
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002121:Calcium Channel Blockers / Q000008:administration & dosage / Q000009:adverse effects*; D002936:Cinnarizine / Q000008:administration & dosage / Q000009:adverse effects*; D003863:Depression / Q000139:chemically induced*; D005260:Female; D005444:Flunarizine / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000453:epidemiology / Q000209:etiology*; D020734:Parkinsonian Disorders / Q000139:chemically induced; D012189:Retrospective Studies; D012307:Risk Factors; D013997:Time Factors
D002121:Calcium Channel Blockers; D002936:Cinnarizine; D005444:Flunarizine